A pharmacokinetic correlation buried in a completed Phase 2 dataset is now driving Actuate Therapeutics’ entire next clinical chapter. The company’s mPDAC trial data — the results that reached statistical significance for overall survival when elraglusib was added to gemcitabine plus nab-paclitaxel — revealed something the IV dosing schedule couldn’t fully exploit: higher systemic exposure to elraglusib tracks directly with better clinical outcomes. That single finding reframes the IV program not as a failure but as a proof-of-concept limited by its own delivery mechanism, and it justifies the FDA-cleared IND for an oral formulation now heading into a Phase 1/2 study in the second half of 2026.
The Phase 1/2 design is straightforward but strategically loaded. The dose-escalation phase will establish MTD and RP2D while generating PK data explicitly intended to show that oral elraglusib achieves higher total exposure than the IV version — a bar the company believes the tablet clears based on preclinical and prior clinical modeling. Once RP2D is confirmed, the expansion cohorts home in on four tumor types: metastatic melanoma, NSCLC, colorectal, and pancreatic cancers. The selection isn’t arbitrary; it reflects both prior IV efficacy signals and machine-learning analyses of therapeutic target expression. Running in parallel, preclinical combination data pairing elraglusib with RAS inhibitors are due mid-2026, with the rationale that a GSK-3β inhibitor targeting NF-kB and DDR pathways could blunt the adaptive resistance that limits RAS-targeted monotherapy — a genuine mechanistic hypothesis, not a positioning exercise.
The regulatory dimension adds real weight. Actuate has already engaged the EMA for guidance on a single registration study design — initially scoped around the IV formulation in mPDAC — and intends to redirect that dialogue toward the oral tablet. Getting both FDA and EMA aligned on a registration-enabling design before Phase 1 even completes is an aggressive sequence, but it compresses the decision tree considerably. It also signals that the company is treating the Phase 1/2 PK readout as the pivotal gate: if oral exposure demonstrably exceeds IV, the path to a registrational pancreatic cancer study opens without requiring an entirely new efficacy dataset.
The number that determines everything here is the oral-to-IV exposure ratio from the Phase 1 PK cohort. If the tablet achieves meaningfully superior AUC, the registration conversation with regulators becomes tractable; if the gap is marginal, the entire exposure-outcome hypothesis loses its clinical leverage.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
